Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Using Network and Spatial Data to Better Target Overdose Prevention Strategies in Rural Appalachia.

Rudolph AE, Young AM, Havens JR.

J Urban Health. 2019 Feb;96(1):27-37. doi: 10.1007/s11524-018-00328-y.

PMID:
30465260
2.

Privacy, Confidentiality, and Safety Considerations for Conducting Geographic Momentary Assessment Studies Among Persons Who Use Drugs and Men Who Have Sex with Men.

Rudolph AE, Young AM, Havens JR.

J Urban Health. 2018 Oct 15. doi: 10.1007/s11524-018-0315-x. [Epub ahead of print]

PMID:
30324355
3.

Spatial Distribution of Partner-Seeking Men Who Have Sex With Men Using Geosocial Networking Apps: Epidemiologic Study.

Algarin AB, Ward PJ, Christian WJ, Rudolph AE, Holloway IW, Young AM.

J Med Internet Res. 2018 May 31;20(5):e173. doi: 10.2196/jmir.9919.

4.

Network-Based Research on Rural Opioid Use: an Overview of Methods and Lessons Learned.

Young AM, Rudolph AE, Havens JR.

Curr HIV/AIDS Rep. 2018 Apr;15(2):113-119. doi: 10.1007/s11904-018-0391-2. Review.

5.
6.
7.

Accuracy of name and age data provided about network members in a social network study of people who use drugs: implications for constructing sociometric networks.

Young AM, Rudolph AE, Su AE, King L, Jent S, Havens JR.

Ann Epidemiol. 2016 Nov;26(11):802-809. doi: 10.1016/j.annepidem.2016.09.010. Epub 2016 Oct 5.

8.

Multiplex Relationships and HIV: Implications for Network-Based Interventions.

Rudolph AE, Crawford ND, Latkin C, Lewis CF.

AIDS Behav. 2017 Apr;21(4):1219-1227. doi: 10.1007/s10461-016-1454-2.

9.

Ethical considerations and potential threats to validity for three methods commonly used to collect geographic information in studies among people who use drugs.

Rudolph AE, Bazzi AR, Fish S.

Addict Behav. 2016 Oct;61:84-90. doi: 10.1016/j.addbeh.2016.05.014. Epub 2016 May 17.

10.

Polydrug Use and HIV Risk Among People Who Inject Heroin in Tijuana, Mexico: A Latent Class Analysis.

Meacham MC, Rudolph AE, Strathdee SA, Rusch ML, Brouwer KC, Patterson TL, Vera A, Rangel G, Roesch SC.

Subst Use Misuse. 2015;50(10):1351-9. doi: 10.3109/10826084.2015.1013132. Epub 2015 Oct 7.

11.

Assessing the geographic coverage and spatial clustering of illicit drug users recruited through respondent-driven sampling in New York City.

Rudolph AE, Young AM, Lewis CF.

J Urban Health. 2015 Apr;92(2):352-78. doi: 10.1007/s11524-015-9937-4.

12.

Nonprescription syringe sales: a missed opportunity for HIV prevention in California.

Pollini RA, Rudolph AE, Case P.

J Am Pharm Assoc (2003). 2015 Jan-Feb;55(1):31-40. doi: 10.1331/JAPhA.2015.14148.

13.

Evaluating outcome-correlated recruitment and geographic recruitment bias in a respondent-driven sample of people who inject drugs in Tijuana, Mexico.

Rudolph AE, Gaines TL, Lozada R, Vera A, Brouwer KC.

AIDS Behav. 2014 Dec;18(12):2325-37. doi: 10.1007/s10461-014-0838-4.

14.

Spatial, temporal and relational patterns in respondent-driven sampling: evidence from a social network study of rural drug users.

Young AM, Rudolph AE, Quillen D, Havens JR.

J Epidemiol Community Health. 2014 Aug;68(8):792-8. doi: 10.1136/jech-2014-203935. Epub 2014 Apr 1.

15.

The Relationship Between Multiple Forms of Discrimination, Neighborhood Characteristics, and Depression Among Illicit Drug Users in New York City.

Crawford ND, White K, Rudolph AE, Jones KC, Benjamin EO, Fuller CM.

J Drug Issues. 2014 Apr;44(2):197-211.

16.

Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States.

Wagner GA, Pacold ME, Kosakovsky Pond SL, Caballero G, Chaillon A, Rudolph AE, Morris SR, Little SJ, Richman DD, Smith DM.

J Infect Dis. 2014 Apr 1;209(7):1032-8. doi: 10.1093/infdis/jit633. Epub 2013 Nov 22. Erratum in: J Infect Dis. 2014 Oct 1;210(7):1166.

17.

Response to letter to the editor: regarding "individual and neighborhood correlates of membership in drug-using networks with a higher prevalence of human immunodeficiency virus (2006-2009)".

Rudolph AE, Crawford ND, Fuller CM.

Ann Epidemiol. 2013 Oct;23(10):666-8. doi: 10.1016/j.annepidem.2013.07.020. Epub 2013 Aug 20. No abstract available.

18.

The longitudinal association of venue stability with consistent condom use among female sex workers in two Mexico-USA border cities.

Gaines TL, Rudolph AE, Brouwer KC, Strathdee SA, Lozada R, Martinez G, Goldenberg SM, Rusch ML.

Int J STD AIDS. 2013 Jul;24(7):523-9. doi: 10.1177/0956462412473890. Epub 2013 Jun 25.

19.

Racial/Ethnic Differences in Recent Drug Detoxification Enrollment and the Role of Discrimination and Neighborhood Factors.

Crawford ND, Rudolph AE, Fuller CM.

Subst Use Misuse. 2014 Jan 1;49(1-2):124-133. doi: 10.3109/10826084.2013.824469. Epub 2013 Aug 21.

20.

Social network members' roles and use of mental health services among drug users in New York City.

Sapra KJ, Crawford ND, Rudolph AE, Jones KC, Benjamin EO, Fuller CM.

J Behav Health Serv Res. 2013 Oct;40(4):476-87. doi: 10.1007/s11414-013-9355-x.

21.

Lessons learned from a survey of the diagnosis and treatment journeys of postmenopausal women with hypertension.

Doner Lotenberg L, Clough LC, Mackey TA, Rudolph AE, Samuel R, Foody JM.

J Clin Hypertens (Greenwich). 2013 Aug;15(8):532-41. doi: 10.1111/jch.12114. Epub 2013 Apr 29.

22.

Individual and neighborhood correlates of membership in drug using networks with a higher prevalence of HIV in New York City (2006-2009).

Rudolph AE, Crawford ND, Latkin C, Fowler JH, Fuller CM.

Ann Epidemiol. 2013 May;23(5):267-74. doi: 10.1016/j.annepidem.2013.02.006. Epub 2013 Mar 21.

23.

The importance of measuring and accounting for potential biases in respondent-driven samples.

Rudolph AE, Fuller CM, Latkin C.

AIDS Behav. 2013 Jul;17(6):2244-52. doi: 10.1007/s10461-013-0451-y.

24.

Individual, network, and neighborhood correlates of exchange sex among female non-injection drug users in Baltimore, MD (2005-2007).

Rudolph AE, Linton S, Dyer TP, Latkin C.

AIDS Behav. 2013 Feb;17(2):598-611. doi: 10.1007/s10461-012-0305-z.

25.

Social and individual risk determinants of HIV testing practices among noninjection drug users at high risk for HIV/AIDS.

White K, Rudolph AE, Jones KC, Latkin C, Benjamin EO, Crawford ND, Fuller CM.

AIDS Care. 2013;25(2):230-8. doi: 10.1080/09540121.2012.701269. Epub 2012 Jul 27.

26.

Differences in self-reported discrimination by primary type of drug used among New York City drug users.

Crawford ND, Rudolph AE, Jones K, Fuller C.

Am J Drug Alcohol Abuse. 2012 Nov;38(6):588-92. doi: 10.3109/00952990.2012.673664. Epub 2012 Apr 23.

27.

Individual, study, and neighborhood level characteristics associated with peer recruitment of young illicit drug users in New York City: optimizing respondent driven sampling.

Rudolph AE, Crawford ND, Latkin C, White K, Benjamin EO, Jones K, Fuller CM.

Soc Sci Med. 2011 Oct;73(7):1097-104. doi: 10.1016/j.socscimed.2011.06.040. Epub 2011 Jul 23.

28.

Perceptions of community- and family-level injection drug user (IDU)- and HIV-related stigma, disclosure decisions and experiences with layered stigma among HIV-positive IDUs in Vietnam.

Rudolph AE, Davis WW, Quan VM, Ha TV, Minh NL, Gregowski A, Salter M, Celentano DD, Go V.

AIDS Care. 2012;24(2):239-44. doi: 10.1080/09540121.2011.596517. Epub 2011 Jul 21.

29.

The association between parental risk behaviors during childhood and having high risk networks in adulthood.

Rudolph AE, Jones KC, Latkin C, Crawford ND, Fuller CM.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):437-43. doi: 10.1016/j.drugalcdep.2011.05.003. Epub 2011 May 31.

30.

Does respondent driven sampling alter the social network composition and health-seeking behaviors of illicit drug users followed prospectively?

Rudolph AE, Latkin C, Crawford ND, Jones KC, Fuller CM.

PLoS One. 2011 May 6;6(5):e19615. doi: 10.1371/journal.pone.0019615.

31.

Subpopulations of illicit drug users reached by targeted street outreach and respondent-driven sampling strategies: implications for research and public health practice.

Rudolph AE, Crawford ND, Latkin C, Heimer R, Benjamin EO, Jones KC, Fuller CM.

Ann Epidemiol. 2011 Apr;21(4):280-9. doi: 10.1016/j.annepidem.2010.11.007.

32.

Progression to type 2 diabetes, healthcare utilization, and cost among pre-diabetic patients with or without comorbid hypertension.

Francis BH, Song X, Andrews LM, Purkayastha D, Princic N, Sedgley R, Rudolph AE.

Curr Med Res Opin. 2011 Apr;27(4):809-19. doi: 10.1185/03007995.2011.554806. Epub 2011 Feb 10.

PMID:
21306287
33.

Correlates of risky injection practices among past-year injection drug users among the US general population.

Ropelewski LR, Mancha BE, Hulbert A, Rudolph AE, Martins SS.

Drug Alcohol Depend. 2011 Jul 1;116(1-3):64-71. doi: 10.1016/j.drugalcdep.2010.11.025. Epub 2011 Jan 11. Erratum in: Drug Alcohol Depend. 2011 Dec 15;119(3):239.

34.

Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens.

Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE.

Curr Med Res Opin. 2010 Dec;26(12):2877-87. doi: 10.1185/03007995.2010.534129. Epub 2010 Nov 11.

PMID:
21067459
35.

A community-based approach to linking injection drug users with needed services through pharmacies: an evaluation of a pilot intervention in New York City.

Rudolph AE, Standish K, Amesty S, Crawford ND, Stern RJ, Badillo WE, Boyer A, Brown D, Ranger N, Orduna JM, Lasenburg L, Lippek S, Fuller CM.

AIDS Educ Prev. 2010 Jun;22(3):238-51. doi: 10.1521/aeap.2010.22.3.238.

36.

Comparison of injection drug users accessing syringes from pharmacies, syringe exchange programs, and other syringe sources to inform targeted HIV prevention and intervention strategies.

Rudolph AE, Crawford ND, Ompad DC, Benjamin EO, Stern RJ, Fuller CM.

J Am Pharm Assoc (2003). 2010 Mar-Apr 1;50(2):140-7. doi: 10.1331/JAPhA.2010.09193.

37.

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.

Amarenco P, Benavente O, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, Gilbert S, Rudolph AE, Simunovic L, Zivin JA, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators.

Stroke. 2009 Apr;40(4):1405-9. doi: 10.1161/STROKEAHA.108.534107. Epub 2009 Feb 19.

PMID:
19228842
38.

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators.

Atherosclerosis. 2009 Jun;204(2):515-20. doi: 10.1016/j.atherosclerosis.2008.09.008. Epub 2008 Sep 18.

PMID:
18962621
39.

Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.

Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.

Curr Med Res Opin. 2008 Jul;24(7):1987-2000. doi: 10.1185/03007990802203279 . Epub 2008 Jun 4. Erratum in: Curr Med Res Opin. 2010 Mar;26(3):631.

PMID:
18554430
40.

Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.

Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.

Clin Ther. 2008 Jan;30(1):195-205. doi: 10.1016/j.clinthera.2008.01.003.

PMID:
18343257
41.

Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators.

Stroke. 2007 Dec;38(12):3198-204. Epub 2007 Oct 25.

PMID:
17962589
42.

High-dose atorvastatin after stroke or transient ischemic attack.

Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.

N Engl J Med. 2006 Aug 10;355(6):549-59. Erratum in: N Engl J Med. 2018 Jun 13;:null.

43.

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.

Hu X, Li S, McMahon EG, Lala DS, Rudolph AE.

Mini Rev Med Chem. 2005 Aug;5(8):709-18. Review.

PMID:
16101407
44.

Emerging therapies for heart failure.

Rudolph AE, McMahon EG.

Expert Opin Emerg Drugs. 2002 Oct;7(2):247-58.

PMID:
15989548
45.

Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction.

Liu YH, Wang D, Rhaleb NE, Yang XP, Xu J, Sankey SS, Rudolph AE, Carretero OA.

J Card Fail. 2005 Feb;11(1):74-81.

PMID:
15704068
46.

Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction.

Masson S, Staszewsky L, Annoni G, Carlo E, Arosio B, Bai A, Calabresi C, Martinoli E, Salio M, Fiordaliso F, Scanziani E, Rudolph AE, Latini R.

J Card Fail. 2004 Oct;10(5):433-41.

PMID:
15470655
47.

Aldosterone target organ protection by eplerenone.

Rudolph AE, Rocha R, McMahon EG.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):229-38. Review.

PMID:
15134822
48.

Role of a selective aldosterone blocker in mice with chronic heart failure.

Wang D, Liu YH, Yang XP, Rhaleb NE, Xu J, Peterson E, Rudolph AE, Carretero OA.

J Card Fail. 2004 Feb;10(1):67-73.

PMID:
14966777
49.

Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.

Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG.

Circ Res. 2003 Jul 11;93(1):69-76. Epub 2003 Jun 5.

PMID:
12791709
50.

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.

Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG.

Kidney Int. 2003 May;63(5):1791-800.

Supplemental Content

Loading ...
Support Center